Bevacizumab biosimilar and reference bevacizumab in subjects with stage IIIB/IV non-squamous non-small cell lung cancer (STELLA): Design of a confirmatory, double-blind, randomized, controlled study.

Yaroslav Shparyk,Igor Bondarenko,Alexandra Paravisini,Amalia Florez,Camino Huerga,Marta Abad,Felicitas Bullo,Susana Millan

Bevacizumab biosimilar and reference bevacizumab in subjects with stage IIIB/IV non-squamous non-small cell lung cancer (STELLA): Design of a confirmatory, double-blind, randomized, controlled study.

2019

Yaroslav Shparyk
Igor Bondarenko
Alexandra Paravisini
Amalia Florez
Camino Huerga
Marta Abad
Felicitas Bullo
Susana Millan

e20731Background: MB02 is a bevacizumab biosimilar developed to stringent guidelines, including non-clinical and preclinical investigations and a clinical trial as first-line treatment in metastati...

Keywords:

Biosimilar
Randomized controlled trial
Oncology
Clinical trial
Bevacizumab
Squamous non-small cell lung cancer
Pathology
Internal medicine
Medicine
Lung cancer
non squamous
double blind
non small cell

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations